CTSNet is happy to share a discussion held between premier planners of the upcoming 37th Annual European Association for Cardiothoracic Surgery (EACTS) Meeting!
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
General
March 24, 2023
Despite the physician compensation decline in 2022, thoracic surgeons received the 2nd highest average salary.
August 30, 2022
August’s top content includes several items from our recent Guest Editor Series, "Segmentectomy for Lung Cancer," from guest editor Alan Sihoe, as well as two uniportal technique videos from thoracic surgeon Diego Gonzalez Rivas.
July 1, 2022
This is an interesting, well-written account of pooled results of two medium-size RCTs . It would be interesting to see a third arm of optimum medical therapy in follow-up studies ...
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
April 19, 2022
Interesting manuscript on the immunology of coronary atheroma, with tanslational potential in therapies and prevention of ischaemic heart disease.
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
December 12, 2021
Interesting early work on the prognostic value in aortic disease of the cross-link component in the elastin.
October 22, 2021
A brief focused commentary on a recent medium size Japanese series of succesful surgery for Acute Aortic Syndrome. The limitations of the series presented in well- written Uchida manuscript( and already to the last AATS Meeting) are being explored, and the commentators' allusion to the need for randomised trial is evident.
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.